Transcatheter Aortic Valve Replacement: An Update in Bicuspid Aortic Valve Disease
Considering the promising outcomes and FDA approval in low-risk patients, the number of transcatheter aortic valve replacement (TAVR) procedures is expected to increase significantly in the coming years. According to the most recent data presented at the American College of Cardiology (ACC) 2020, bicuspid aortic valve disease (BAV) patients who undergo TAVR procedures had a low risk of death or disabling stroke and high rate of success with a newer self-expanding artificial valve (Evolut supra-annular self-expanding valves, Medtronic). Further, BAV patients reported to have a similar rate of death compared with tricuspid aortic valve disease patients following TAVR using the balloon-expandable valve (Edwards Sapien 3, Edwards Lifesciences).
Improving efficacy and reduction in operator variability is essential to ensure the adoption of TAVR for BAV patients. In particular, the BAV morphologies will remain challenging and require accurate pre- and peri-procedural work up.
This programme has therefore been designed for an audience of cardiologists and surgeons to build their understanding of bicuspid valve disease and classifications, clinical trial data supporting TAVR in low-risk bicuspid patients, implant techniques, and device considerations for bicuspid patients.
This programme is intended to educate:
- Interventional cardiologists
- General cardiologists
- Describe the latest data in bicuspid valve disease and understand the classifications
- Critically evaluate clinical trial data in TAVR in low-risk bicuspid patients
- Review implant techniques and device considerations for bicuspid patients
In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
This activity has been supported by an unrestricted educational grant from Medtronic.
R-CME Disclaimer / Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
Part 1 - Programme introduction and TAVR in low risk bicuspid patients: critical review of the clinical evidence (Prof Nicolas Van Mieghem, Dr Basel Ramlawi)
Part 2 - Implant techniques and devices selections for bicuspid patients (Dr Didier Tchetche, Prof Nicolas Van Mieghem)
Part 3 - TAVR in bicuspid patients: Case reviews (Dr Firas Zahr, Prof Nicolas Van Mieghem)
Part 4 - Discussion and Q&As (Prof Nicolas Van Mieghem, Dr Basel Ramlawi, Dr Didier Tchetche, Dr Firas Zahr)
Prof Nicolas Van Mieghem, Erasmus Medical Center, Rotterdam, NL
Dr Basel Ramlawi, Valley Health System, Virginia, US
Dr Didier Tchetche, Clinique Pasteur, Toulouse, FR
Dr Firas Zahr, Oregon Health and Science University, US
The event ‘Transcatheter Aortic Valve Replacement: An Update In Bicuspid Aortic Valve Disease’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
1.00 European Board for Accreditation in Cardiology (EBAC)
This video series was funded by an unrestricted educational grant from Medtronic.
- 1.00 European Board for Accreditation in Cardiology (EBAC)